Assembly Biosciences
ASMB
106 hedge funds and large institutions have $700M invested in Assembly Biosciences in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 23 reducing their positions, and 8 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 23
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
56% more capital invested
Capital invested by funds: $449M → $700M (+$251M)
8% more funds holding
Funds holding: 98 → 106 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 7.73% → 7.64% (-0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.29M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$6.86M |
| 4 |
BlackRock
New York
|
+$4.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$32.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.98M |
| 3 |
Morgan Stanley
New York
|
-$2.82M |
| 4 |
AC
Armistice Capital
New York
|
-$2.49M |
| 5 |
JP Morgan Chase
New York
|
-$1.49M |
ASMB Hedge Fund Activity: Q2 2020 in Review
106 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2020, worth a combined $700M — up 56% from $449M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ASMB positions and 8 closed out — a net gain of 8 holders — while 49 added to existing stakes and 23 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $10.9M. The largest seller was Victory Capital Management, cutting an estimated $32.9M.
- 106 institutional investors held Assembly Biosciences (ASMB) as of Q2 2020, up from 98 in Q1 2020.
- Funds reported $700M of Assembly Biosciences stock for Q2 2020, up 56% quarter-over-quarter.
- 16 funds opened new Assembly Biosciences positions in Q2 2020 and 8 closed out, a net change of +8 holders.
- The largest Assembly Biosciences buyer in Q2 2020 was EcoR1 Capital, an estimated $10.9M added.
- The largest Assembly Biosciences seller in Q2 2020 was Victory Capital Management, an estimated $32.9M sold.
Based on aggregated 13F filings for Q2 2020.